Specializing in structure-based protein design, the company develops anti-angiogenic therapies for cancer, autoimmune, and rare diseases using proprietary tri-specific antibody technology to enhance therapeutic efficacy. Current projects include Phase I trials for new drug candidates and partnerships for manufacturing and development.